Thyme Care Raises $97M Series D in Latest Funding Round

Thyme Care has successfully closed a $97M Series D funding round, marking a significant milestone in the company's growth trajectory. The round was led by Multiple venture and strategic backers, with participation from .

Company Overview

Founded in 2018 and headquartered in Nashville, TN, Thyme Care has established itself as a leader in the healthtech space. Value-based oncology care platform that improves outcomes and reduces costs for cancer patients

With a current valuation of $750M, the company has demonstrated strong market traction and investor confidence. The organization currently employs 200-300 people and continues to scale its operations.

Investment Details

Funding Round Highlights

• Amount Raised: $97M Series D
• Valuation: $750M
• Lead Investor: Multiple venture and strategic backers
• Round Type: Series

Key Investors

The funding round saw participation from several notable investors:

• Multiple venture and strategic backers: Strategic investor in the technology and growth company space

Market Context

The HealthTech sector continues to attract significant investor interest, with companies focusing on automation, AI integration, and operational efficiency seeing particularly strong funding activity. This investment reflects the growing demand for innovative solutions in this space.

Growth Strategy

With this latest funding, Thyme Care plans to:

• Accelerate product development and innovation
• Expand market reach and customer acquisition
• Scale engineering and go-to-market teams
• Strengthen competitive positioning in the healthtech market

Industry Impact

Thyme Care's funding round represents the continued evolution of the healthtech industry, where technology-driven solutions are becoming increasingly critical for business success. The company's approach to improving healthcare delivery and patient outcomes through technology positions it well for future growth.

Future Outlook

As Thyme Care moves forward with its expanded funding, the company is well-positioned to capitalize on market opportunities and drive innovation in the healthtech space. Industry experts expect continued growth and potential for additional strategic partnerships.

The investment validates the company's business model and growth potential, setting the stage for the next phase of expansion and market leadership.